EL7.AI
StocksMediumUpdated•Originally published 30 September 2026•Updated 30 September 2026•
1 min read

Connect Biopharma Reports Mixed Phase 2 Results for Rademikibart in COPD

Key Facts

1Connect Biopharma announced positive preliminary topline Phase 2 data for Rademikibart as a treatment for acute exacerbations in adults with COPD.
2The drug reduced the rate of treatment failure by 81% compared to placebo through one month, with a p-value of 0.0122.

Connect Biopharma announced mixed results from its Phase 2 study of Rademikibart for treating acute exacerbations in adults with chronic obstructive pulmonary disease (COPD). According to a statement released via GlobeNewswire, while the drug reduced the rate of treatment failure by 81% and achieved a 100% reduction in emergency admissions, it failed to reach statistical significance for the secondary lung function endpoint (FEV1) at Day 7.

The study evaluated Rademikibart as an add-on treatment for patients with Type 2 inflammation to improve outcomes following acute respiratory events. Regarding market performance, CNTB closed at $0.992 on September 29, 2026, with the session seeing a high of $1.09 and a low of $0.98 prior to the release of these clinical findings.